Editor’s Note: This op-ed was originally published in STAT on January 17, 2025.
President Biden took a groundbreaking step in proposing to cover GLP-1 obesity medications under Medicare and Medicaid in November. But on Friday, his administration announced that Wegovy, one of these drugs, would be subject to price controls. This is a surefire way to crush innovation and discourage new entrants to this important new class of medicines that could help millions of Americans.
GLP-1s, or glucagon-like peptide-1 receptor agonists, are safe and effective. They not only help people lose weight but also reduce the risk of diabetes, cardiovascular disease, and potentially fight addiction to alcohol, illicit drugs, and opioids — key priorities from President-elect Trump’s first term that also have huge potential to lower health care costs. They can play a substantial role in Trump’s Make America Healthy Again (MAHA) initiative, and potentially help rein in excessive government spending as the Department of Government Efficiency (DOGE) intends.
Even Robert F. Kennedy Jr., Trump’s choice to lead the Department of Health and Human Services and no friend of the drug companies, acknowledged that “GLP drugs have a place” in the MAHA initiative. And Elon Musk, who will lead DOGE, noted on X, “Nothing would do more to improve the health, lifespan and quality of life for Americans than making GLP inhibitors super low cost to the public.”
The question for Trump is: How do we go about it in the most cost-effective way? Allowing Medicare to cover these medications is a great place to start.
The Food and Drug Administration recently elevated obesity to a “chronic disease,” no longer just a “relapsing health risk.” This is a significant shift that gets the Centers for Medicare and Medicaid Services and the FDA on the same page. Medicare’s statute forbidding coverage of weight loss drugs was written to prevent coverage for unproven drugs like Dexatrim and fen-phen, not to limit access to proven chronic disease interventions like GLP-1s. To its credit, the Biden White House proposed a new rule in November 2024 that would expand coverage of these medications under Medicare and Medicaid. But to lower costs, Medicare announced that Wegovy will be added to the agency’s Inflation Reduction Act price controls.
Even Robert F. Kennedy Jr., Trump’s choice to lead the Department of Health and Human Services and no friend of the drug companies, acknowledged that “GLP drugs have a place” in the MAHA initiative. And Elon Musk, who will lead DOGE, noted on X, “Nothing would do more to improve the health, lifespan and quality of life for Americans than making GLP inhibitors super low cost to the public.”
The question for Trump is: How do we go about it in the most cost-effective way? Allowing Medicare to cover these medications is a great place to start.
The Food and Drug Administration recently elevated obesity to a “chronic disease,” no longer just a “relapsing health risk.” This is a significant shift that gets the Centers for Medicare and Medicaid Services and the FDA on the same page. Medicare’s statute forbidding coverage of weight loss drugs was written to prevent coverage for unproven drugs like Dexatrim and fen-phen, not to limit access to proven chronic disease interventions like GLP-1s. To its credit, the Biden White House proposed a new rule in November 2024 that would expand coverage of these medications under Medicare and Medicaid. But to lower costs, Medicare announced that Wegovy will be added to the agency’s Inflation Reduction Act price controls.
Under Biden, the Department of Health and Human Services’ budget ballooned to $1.9 trillion, offering DOGE plenty of space for cuts that should create room for investing in patient health through GLP-1 coverage. Biden’s nursing home rule would cost $17 billion and lead to facilities closing down. Additionally, Biden has sought to saddle vulnerable Americans with expensive and ineffective coverage through a rule expanding Obamacare at the expense of employer coverage and a rule that reduces the frequency of Medicaid eligibility verifications, preventing resources from going to those most in need. Repealing these would save $34 billion and $200 billion, respectively.
Chronic diet-related diseases cost nearly half a trillion dollars to treat. The Joint Economic Committee estimates government spending on obesity will exceed $4 trillion by 2033. We must reduce these costs, and done right, expanding access to obesity medications can help make a real dent and improve life for millions of Americans.
A nonresident senior scholar at the USC Schaeffer Institute, Joe Grogan served as White House Domestic Policy Council director to President Trump, 2019-20. He has also served as the Associate Director of Health Programs at the Office of Management and Budget.
Sign up for Schaeffer Center news